Sheridan Capital Partners Divests Diamondback Drugs

CHICAGO, IL – Sheridan Capital Partners (“Sheridan”) announced today the sale of Scottsdale, AZ-based Diamondback Drugs, LLC (“Diamondback” or the “Company”) to Tailwind Capital. Diamondback is a leading national veterinary compounding pharmacy, serving veterinary clinics, veterinary hospitals, zoos, aquariums, research institutions, and individual pet owners. The Company provides the most extensive and advanced veterinary compounded pharmaceutical offering available, ranging from ophthalmic preparations to cancer treatment solutions.

“It has been a pleasure working alongside Diamondback’s remarkable management team to build a market leading veterinary pharmacy,” said Jonathan Lewis, Managing Partner at Sheridan. “The exit marks a tremendous outcome for Sheridan, our investors and the Diamondback management team.”

“Sheridan’s investment allowed us to build upon our core strength of offering quality, customized products to pet owners and veterinarians, further extend our offering, and improve our operations while continuing to deliver outstanding service,” said Michael Blaire, Chief Executive Officer at Diamondback. “As a result of our partnership with Sheridan, Diamondback is well-positioned to grow its leading market share and to continue to deliver critical medications for pets.”

Financial terms of the transaction are not being disclosed. Deloitte Corporate Finance LLC served as the Company’s advisor.